New Paper (Other): Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

[marouenbg]

Title: Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

General Information

Please paste a link to the paper or a citation here:

Link: https://www.sciencedirect.com/science/article/pii/S0092867420314562

What is the paper's Manubot-style citation?

Citation: [@doi:10.1016/j.cell.2020.10.049]

Is this paper primarily relevant to Background or Pathogenesis?

• [ ] Background
• [x] Pathogenesis
• [ ] Methods

Please list some keywords (3-10) that help identify the relevance of this paper to COVID-19

• keyword 1 convalescent plasma
• keyword 2 immunocompromised
• keyword 3 COVID-19

Please note the publication / review status

• [ ] Pre-print
• [x] New Peer-Reviewed Paper
• [ ] Peer-Reviewed Paper Pre-2020

Which areas of expertise are particularly relevant to the paper?

• [x] virology
• [ ] epidemiology
• [ ] biostatistics
• [x] immunology
• [ ] pharmacology
• [ ] other:

[marouenbg]

Summary

Suggested questions to answer about each paper:

• What did they analyze? A case study in an immunocompromised patient that was positive for SARS-CoV-2 for than 100 days after initial diagnosis.

• What methods did they use? Longitudinal genomic analysis of nasopharyngeal swabs.

• Does this paper study COVID-19, SARS-CoV-2, or a related disease and/or virus? This paper studies the accelerated evolution of SARS-CoV-2 in immunocompromised patients.

• What is the main finding (or a few main takeaways)? Two factors could promote an accelerated evolution of SARS-CoV-2: 1) immunodeficiency and 2) treatment with convalescent plasma that could induce a selection pressure to develop escape mutations.

• What does this paper tell us about the background and/or diagnostics/therapeutics for COVID-19 / SARS-CoV-2? This paper provides new information about the resistance of SARS-CoV-2 to antibody treatment, potentially suggesting that convalescent plasma transfusions could promote the emergence of escape variants.

• Do you have any concerns about methodology or the interpretation of these results beyond this analysis? None.

Any comments or notes?